-
-
-
-
-
-
-
NKGen receives FDA expanded access authorization for neurodegenerative therapy
-
-
-
-
-
-
-
Monte Rosa begins dosing patients in phase 1 trial of MRT-8102
-
-
-
-
-
-
-
Cloudbreak Pharma reports positive phase 2 results for eye drop CBT-004
-
-
-
-
-
-
-
CEA Industries sees opportunity in FDA authorization of JUUL products
-
-
-
-
-
-
-
Precision BioSciences gets FDA orphan drug designations for DMD treatment
-
-
-
-
-
-
-
DiaMedica reports positive interim results from preeclampsia trial
-
-
-
-
-
-
-
Innovent Biologics' cancer drug shows promise in phase 1 trial
-
71,244 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.